Company UpdateNewspaper Publication
Financial ServicesFinanceOther Financial Services
Relic Technologies Ltd
Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 39 filings·Updated 15 Aug 2026
Showing 10 of 39 filings.
15 Aug 20262 filings
AGM/EGMAGM
Relic Technologies' 2026 AGM approves eight resolutions including ESOPs and RPT with subsidiary
AGM Details
- AGM held on 13 August 2026 at 12:30 PM via Video Conferencing/OAVM.
- Remote e-voting period: 10–12 August 2026.
- Voting cut-off date: 6 August 2026.
Ordinary resolutions
- Item 1: Adoption of standalone and consolidated financial statements; passed.
- Item 2: Re-appointment of Kunal Gandhi as Director; passed.
- Item 3: Appointment of Radhika Shriram as Non-Executive Director; passed.
- Item 4: Appointment of Sachin Srivastava as Director; passed.
Special resolutions
- Item 5: Appointment of Sachin Srivastava as Whole Time Director and CEO; passed.
- Item 6: Approval for material related party transactions with Truhealthy Wellness Private Limited; passed.
- Item 7: Approval for Employee Stock Option Plan (ESOP) for the Company; passed.
- Item 8: Extension of ESOP 2025 to employees of subsidiary companies; passed.
Director changes
- Re-appointment of Kunal Gandhi as Director (retiring by rotation); passed.
- Ms. Radhika Shriram appointed as Non-Executive Director; passed.
- Sachin Srivastava appointed as Director and later as Whole Time Director & CEO.
Related party transactions
- RPT with Truhealthy Wellness Private Limited (subsidiary) approved; value not disclosed.
13 Aug 20264 filings
AGM/EGMAGM
Relic Technologies holds 35th AGM via VC with director changes and ESOP approvals
AGM Details
- Held on 13 August 2026, 12:30 PM–1:20 PM via VC/OAVM.
- Venue deemed at registered office.
- Remote e-voting: Aug 10–12, 9:00 AM–5:00 PM.
- Quorum present via video conference.
- Proxy facility not available; no proxies counted.
Resolutions Proposed
- Ordinary: Adopt audited standalone and consolidated financial statements for FY26.
- Ordinary: Re-appoint director retiring by rotation.
- Special: Appoint Ms. Radhika Shriram as Non-Executive Director.
- Special: Appoint Mr. Sachin Srivastava as Director.
- Special: Appoint Mr. Sachin Srivastava as Whole-Time Director and CEO.
- Special: Approve material related party transactions with Truhealthy Wellness Private Limited.
- Special: Approve ESOP for the Company.
- Special: Extend ESOP 2025 benefits to employees of subsidiary companies.
Voting Status
- Voting results pending; Scrutinizer to submit report.
- Results to be displayed on company and stock exchange websites within 48 hours.
Director Changes
- Kunal Gandhi to continue as director, retiring by rotation.
- Radhika Shriram appointed as Non-Executive Director.
- Sachin Srivastava appointed as Director and Whole-Time Director/CEO.
Auditor & Related Parties
- No auditor appointments or changes announced.
- RPT with subsidiary Truhealthy Wellness Private Limited included as a special resolution.
ESOP and Related Approvals
- ESOP for the Company approved; extension to subsidiary employees.
Company UpdateReg. 32 (1), (3) - Statement of Deviation & Variation
Relic Technologies reports no deviation in funds from preferential issue for quarter ended 30 June 2026
Deviation status and utilisation
- No deviation in the use of funds raised from the preferential issue for the quarter.
- Audit Committee reviewed and confirmed alignment with the objects.
- Fundraising dates: 5 April 2025 (equity); 13 December 2025 (warrant conversion to equity).
- Total proceeds raised: Rs 1317.50 Lakhs in equity; Rs 374.98 Lakhs for warrants.
- Utilisation status as of 30/06/2026: cumulative Rs 625.50 Lakhs utilised.
- Monitoring agency: Not applicable.
- There is no deviation or variation per the quarter's report.
ResultFinancial Results
Relic Technologies Q1 FY27: Consolidated revenue 35.49 lakhs, net loss 102.75 lakhs, EPS -1.16
Consolidated results
- Consolidated revenue from operations for the quarter ended June 30, 2026: 35.49 lakhs.
- Total consolidated income for the quarter: 57.86 lakhs.
- Total consolidated expenses: 162.07 lakhs.
- Net profit after tax for the quarter: loss of 102.75 lakhs.
- Basic and diluted EPS stood at -1.16 each.
- Total comprehensive income for the period: loss of 101.28 lakhs.
- Note: commenced revenue from trading activities in pharmaceuticals, nutraceuticals, wellness, healthcare, chemicals.
Board MeetingOutcome of Board Meeting
Relic Technologies approves Q1 FY2026-27 unaudited standalone and consolidated results with unmodified Limited Review
Financial results and revenue initiation
- Unaudited standalone and consolidated quarterly results for quarter ended June 30, 2026 approved.
- Limited Review Reports with unmodified opinion issued for both standalone and consolidated results.
- Revenue from operations commenced in quarter ended June 30, 2026 via trading activities in pharmaceuticals and related products.
28 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Reg 74(5) certificate confirms dematerialisation processing up to 30 June 2026 and listings.
Dematerialisation status and certificate actions
- Securities received for dematerialisation up to 30 June 2026 were confirmed to depositories; listed on the exchange.
- Physical certificates dematerialised were mutilated and cancelled; depository's name substituted as registered owner within 15 days.
18 Jul 20261 filing
Company UpdateNewspaper Publication
Newspaper Publication of Pre-dispatch of 35th Annual General Meeting Notice
13 Jun 20262 filings
Company UpdateResignation of Director
Relic Technologies Ltd - 511712 - Announcement under Regulation 30 (LODR)-Resignation of Director
Resignation
- Mr. Karthik Swaminathan Iyer resigned as Executive Director of Relic Technologies Limited.
- Resignation was effective 13 June 2026.
- He cited personal and health reasons for resigning.
- He stated no other material reasons beyond those disclosed.
- He will also cease to be a director of the company.
Company UpdateChange in Management
Relic Technologies Ltd - 511712 - Announcement under Regulation 30 (LODR)-Change in Management
Appointment
- Mr. Sachin Srivastava appointed Whole Time Director and CEO effective 13 June 2026.
- He was first appointed as Additional Director, then as Whole Time Director and CEO.
- He has nearly 25 years' experience in pharmaceutical sales, marketing, and management.
- No relationship with other directors was disclosed.
Resignation
- Mr. Karthik Iyer resigned as Executive Director effective 13 June 2026.
- He also ceased to be a director of the company.
- He cited personal and health reasons for resignation.
Showing 10 of 39 filings